Samsung Biologics, South Korea’s leading contract development and manufacturing organisation (CDMO), has announced its financial results for the second quarter of fiscal year 2025, posting strong growth across both consolidated and standalone metrics.

The company recorded consolidated revenue of KRW 1,289.9 billion (approximately USD 941.63 million) and an operating profit of KRW 475.6 billion (approximately USD 347.19 million).

On a standalone basis, its revenue was reported at KRW 1,014.2 billion (USD 740.37 million), with operating profit reaching KRW 477.0 billion (USD 348.21 million).

Samsung Biologics attributed the growth to the full utilisation of Plants 1 through 3 and the continued ramp-up of Plant 4.

For the first half of 2025, standalone revenue surpassed KRW 2 trillion (approximately USD 1.46 billion), reflecting consistent momentum across all manufacturing plants.

The company’s sales contract volume in the first half reached USD 2.4 billion, raising its cumulative value to USD 18.7 billion.

"Our second quarter results demonstrate continued strong momentum across our business," said John Rim, CEO and President of Samsung Biologics.

"With Plant 5 now fully operational, we are leveraging our manufacturing expertise and expanded capacity to deliver seamless, end-to-end CDMO services at scale. We have broadened our portfolio with advancements in antibody-drug conjugates (ADCs) and the launch of research services, Samsung Organoids, further reinforcing our ability to offer a wider range of innovative solutions to clients.”

“Additionally, we are redefining digitalization in biomanufacturing, harnessing advanced digital tools to deliver greater transparency, speed, and value—setting new standards in the industry. These strategic initiatives will continue to strengthen our ability to accelerate client pipelines, while fostering enduring partnerships grounded in quality and operational excellence,” he added.

In April, the company added 180 kL of capacity with Plant 5, which is equipped with advanced automation and digital systems.

The company also broadened its service offering with the launch of research services, Samsung Organoids, which utilises patient-derived organoids to support drug discovery and development.

In May, the company announced plans to spin off its wholly-owned subsidiary, Samsung Bioepis, to focus on strengthening its core capabilities as a pure-play CDMO.

On the sustainability front, the company released its 2025 ESG report in June, outlining progress in areas including enhanced disclosure standards, an accelerated path to net-zero, and TNFD-aligned risk management.

With a combined biomanufacturing capacity of 784 kL across five plants, Samsung Biologics offers end-to-end integrated services that range from late discovery to commercial manufacturing.

The company maintains a global footprint, with facilities and offices in Korea, the US, and Japan. While Samsung Biologics America supports clients in the US and Europe, its Tokyo office caters to the broader Asia-Pacific region.